Pre-made Visilizumab benchmark antibody ( Whole mAb, anti-CD3E therapeutic antibody, Anti-T3E/TCRE/IMD18/CD3epsilon Antibody) for drug discovery and mechanism of action (MOA) research

Cat:GMP-Bios-ab-622

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

SKU GMP-Bios-ab-622 Category Tag

Product Details

Pre-Made Visilizumab biosimilar, Whole mAb, Anti-CD3E Antibody: Anti-T3E/TCRE/IMD18/CD3epsilon therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Visilizumab (tentative trade name Nuvion, PDL BioPharma Inc.) is a humanized monoclonal antibody. It is being investigated for use as an immunosuppressive drug in patients with ulcerative colitis and Crohn’s disease. Visilizumab binds to the CD3 receptor on certain activated T cells without affecting resting T cells. It is currently under clinical studies for the treatment of ulcerative colitis and Crohn’s disease.

Products Name (INN Index)

Pre-Made Visilizumab biosimilar, Whole mAb, Anti-CD3E Antibody: Anti-T3E/TCRE/IMD18/CD3epsilon therapeutic antibody

INN Name

Visilizumab

Target

CD3E

Format

Whole mAb

Derivation

NA

Species Reactivity

Human

CH1 Isotype

IgG2

VD LC

nd

Highest_Clin_Trial (Jan '20)

Phase-III

Est. Status

Discontinued

100% SI Structure

None

99% SI Structure

None

95-98% SI Structure

None

Year Proposed

2000

Companies

PDL BioPharma

Conditions Approved

NA

Conditions Active

NA

Conditions Discontinued

Crohn's disease,Graft-versus-host disease,Psoriasis,Renal transplant rejection,Ulcerative colitis

Development Tech

NA

Previous Name

NA

Gm Offical Target Name

CD3E

Package

, ,

Genemeidi Omicron Variant Products
test
Previous slide
Next slide